Eventide Asset Management’s Fennec Pharmaceuticals FENC Stock Holding History

Eventide Asset Management’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,040,000	Closed	-$6.46M	–	155
2021 Q1	$6.46M	Sell	1,040,000 -80,000	-7%	-$602K	0.1%	126
2020 Q4	$8.34M	Hold	1,120,000	–	–	0.13%	114
2020 Q3	$6.79M	Hold	1,120,000	–	–	0.13%	108
2020 Q2	$9.35M	Buy	1,120,000 +400,000	+56%	+$2.97M	0.2%	97
2020 Q1	$4.28M	Hold	720,000	–	–	0.14%	95
2019 Q4	$4.67M	Hold	720,000	–	–	0.13%	83
2019 Q3	$3.46M	Hold	720,000	–	–	0.11%	86
2019 Q2	$2.88M	Hold	720,000	–	–	0.09%	93
2019 Q1	$3.49M	Hold	720,000	–	–	0.12%	95
2018 Q4	$4.59M	Sell	720,000 -21,175	-3%	-$148K	0.2%	87
2018 Q3	$6.08M	Hold	741,175	–	–	0.22%	97
2018 Q2	$7.74M	Hold	741,175	–	–	0.32%	83
2018 Q1	$8.96M	Hold	741,175	–	–	0.42%	67
2017 Q4	$7.39M	Buy	+741,175	New	+$7.4M	0.39%	68

Other funds holding FENC

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Eventide Asset Management's FENC Position: Q2 2021 in Review

Eventide Asset Management sold out of Fennec Pharmaceuticals (FENC) in Q2 2021, closing a stake of 1,040,000 shares — an estimated $6.46M sold.

Eventide Asset Management first reported a position in FENC in Q4 2017 and held it in 14 quarters. The position peaked at $9.35M in Q2 2020. 39 funds tracked by Wall St. Rank hold FENC as of Q2 2021.

Eventide Asset Management reported no remaining Fennec Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Eventide Asset Management sold 1,040,000 Fennec Pharmaceuticals shares in Q2 2021, an estimated $6.46M.
Eventide Asset Management first reported a position in Fennec Pharmaceuticals in Q4 2017 and held it in 14 quarters.
Eventide Asset Management's Fennec Pharmaceuticals position peaked at $9.35M in Q2 2020.
39 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2021.

Based on Eventide Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.